Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009A (H1N1) influenza virus

Viral Immunology

Volumn 24, Issue 5, 2011, Pages 369-374

  Xu, Chun'E ^a   Song, Xiaohong ^a   Fu, Ling ^a   Dong, Dayong ^a   Wu, Shipo ^a   Li, Guanlin ^a   Yi, Shaoqiong ^a   Yu, Ting ^a   Yu, Rui ^a   Hou, Lihua ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 1A; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BETA1A INTERFERON; MYXOVIRUS RESISTANCE PROTEIN; OMEGA INTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN; CELL STRAIN CACO 2; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFECT; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; NONHUMAN; PROTEIN EXPRESSION; VIRUS LOAD; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; CACO-2 CELLS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INTERFERON TYPE I; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; RECOMBINANT PROTEINS; VIRUS REPLICATION;

CAVIA; ORTHOMYXOVIRIDAE;

EID: 80054722840     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0003     Document Type: Article

References (20)

1. Durbin JE, Fernandez-Sesma A, Lee CK, et al.: Type I IFN modulates innate and specific antiviral immunity. J Immunol 2000;164:4220-4228. (Pubitemid 30215081)
2. Jewell NA, Vaghefi N, Mertz SE, et al.: Differential type I interferon induction by respiratory syncytial virus and influenza A virus in vivo. J Virol 2007;81:9790-9800. (Pubitemid 350067683)
3. Van Hoeven N, Belser JA, Szretter KJ, et al.: Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol 2009;83:2851-2861.
4. Beilharz MW, Cummins JM, and Bennett AL: Protection from lethal influenza virus challenge by oral type 1 inter-feron. Biochem Biophys Res Commun 2007;355:740-744. (Pubitemid 46330215)
5. Kugel D, Kochs G, Obojes K, et al.: Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 2009;83:3843-3851.
6. Herzog C, Berger R, Fernex M, Friesecke K, Havas L, Just M, and Dubach UC: Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo controlled field study. Antivir Res 1986;6:171-176. (Pubitemid 16076704)
7. Adolf GR: Human omega interferon-a review. Multiple Sclerosis 1995;1:S44-S47.
8. Oritani K, Kincade PW, Zhang C, Tomiyama Y, and Mat-suzawa Y: Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 2001;12:337-348. (Pubitemid 32851746)
9. Buckwold VE, Wei J, Huang Z, et al.: Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antivir Res 2007;73:118-125. (Pubitemid 46138065)
10. Garten RJ, Davis CT, Russell CA, et al.: Antigenic and genetic characteristics of swine-origin 2009A (H1N1) influenza viruses circulating in humans. Science 2009;325:197-201.
11. Maines TR, Jayaraman A, Belser JA, et al.: Transmission and pathogenesis of swine-origin 2009A (H1N1) influenza viruses in ferrets and mice. Science 2009;325;484-487.
12. Steel J, Staeheli P, Mubareka S, Garćia-Sastre A, Palese P, and Lowen AC: Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol 2010;84:21-26.
13. Qi L, Fu L, Yu C, Yu T, Xu C, Wang H, and Chen W: Expression and purification of human interferon omega in yeast Pichia pastoris. Bull Acad Mil Med Sci 2003;27:268-270 (Chinese).
14. Finney D: Statistical Method in Biological Assay. Charles Griffin, London, 1952, pp. 524-530.
15. Haller O, Staeheli P, and Kochs G: Protective role of inter-feron-induced Mx GTPases against influenza viruses. Rev Sci Tech 2009;28:219-231.
16. Arnheiter H, Frese M, Kambadur R, Meier E, and Haller O: Mx transgenic mice-animal models of health. Curr Top Microbiol Immunol 1996;206:119-147.
17. Hovanessian, A: On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2¢-5¢-oligoa-denylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev 2007;18:351-361. (Pubitemid 47302823)
18. Galasso GJ, Younger JS, and Glasgow LA: Antiviral research in the Soviet Union. J Infect Dis 1972;125:455-456.
19. Jordan WS, Hopps HE, and Merigan TC: Influenza and interferon research in the Soviet Union. J Infect Dis 1973;128: 261-264.
20. Li IW, Chan KH, To KW, et al.: Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. J Clinic Virol 2009;46:325-330.